Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monitoring low molecular weight heparins.

Jack E Garon1

  • 1Chicago Medical School, Mt. Sinai Hospital, Chicago, Illinois, USA.

Clinical Leadership & Management Review : the Journal of CLMA
|February 21, 2003
PubMed
Summary

Low molecular weight heparin (LMWH) is a key treatment for thrombotic disorders. Monitoring its anti-Xa activity is crucial in specific patient groups, utilizing chronometric or chromogenic assays.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accurate preoperative diagnosis of ovarian pregnancy with transvaginal scan.

Case reports in obstetrics and gynecology·2012
Same author

Con: Licensure unnecessary in the clinical laboratory.

Clinical leadership & management review : the journal of CLMA·2006
Same author

Patient safety and the preanalytic phase of testing.

Clinical leadership & management review : the journal of CLMA·2004
Same author

Metastatic pure small-cell carcinoma of prostate.

The American journal of the medical sciences·2004
Same author

Facilitating meetings.

Clinical leadership & management review : the journal of CLMA·2002
Same author

Recent advances in parathyroid disease and parathyroid hormone assays.

Clinical leadership & management review : the journal of CLMA·2002

Area of Science:

  • Pharmacology and Therapeutics
  • Clinical Chemistry

Background:

  • Low molecular weight heparin (LMWH) is widely used for treating thrombotic disorders.
  • Understanding its clinical applications, mechanisms, and potential complications is essential for safe and effective use.

Purpose of the Study:

  • To review the clinical indications for Low molecular weight heparin (LMWH) therapy.
  • To discuss the pharmacology and potential complications associated with LMWH treatment.
  • To highlight specific patient populations requiring monitoring and compare available assay methods.

Main Methods:

  • Review of clinical indications for Low molecular weight heparin (LMWH).
  • Examination of LMWH pharmacology and associated complications.
  • Analysis of monitoring requirements in renal failure, obesity, pregnancy, and pediatric patients.
  • Comparison of chronometric (clotting) and chromogenic (amidolytic) assay types for anti-Xa activity.

Main Results:

  • Specific clinical scenarios necessitate monitoring of Low molecular weight heparin (LMWH) therapy.
  • Monitoring typically assesses the anti-Xa properties of LMWH.
  • Both chronometric and chromogenic assays are viable methods for measuring anti-Xa activity, each with distinct characteristics.

Conclusions:

  • Low molecular weight heparin (LMWH) therapy requires careful consideration of indications, pharmacology, and complications.
  • Monitoring anti-Xa activity is vital in certain patient populations, including those with renal failure, obesity, pregnancy, and pediatric patients.
  • The choice between chronometric and chromogenic assays depends on specific laboratory and clinical needs for assessing LMWH efficacy and safety.

Related Experiment Videos